N/A
N=45
A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
COVID-19 · Influenza
Bottom Line
View on ClinicalTrials.gov: NCT05674370 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcome: Primary: Positive Percent Agreement — 52 percent of nasal swabs
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- GRIP Electronic Diagnostic Chip (Device); Laboratory-based nucleic acid amplification tests (NAATs) (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive Percent Agreement |
52 | — |
| PRIMARY Negative Percent Agreement |
44 | — |
Summary
The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.
Eligibility Criteria
Inclusion Criteria
- Patients being tested for COVID 19 or Influenza
Exclusion Criteria
- Patients < 18 years of age
Data sourced from ClinicalTrials.gov (NCT05674370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.